Literature DB >> 16094414

Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis.

A Seftel1.   

Abstract

Male hypogonadism has a multifactorial etiology that includes genetic conditions, anatomic abnormalities, infection, tumor, and injury. Defects in the hypothalamic-pituitary-gonadal axis may also result from type II diabetes mellitus and treatment with a range of medications. Circulating testosterone levels have been associated with sexual function, cognitive function, and body composition. Apart from reduced levels of testosterone, clinical hallmarks of hypogonadism include absence or regression of secondary sex characteristics, reduced fertility (oligospermia, azoospermia), anemia, muscle wasting, reduced bone mass (and bone mineral density), and/or abdominal adiposity. Some patients, particularly those with partial androgen deficiency of the aging male, also experience sexual dysfunction, reduced sense of vitality, depressed mood, increased irritability, difficulty concentrating, and/or hot flushes in certain cases of acute onset. As many patients with male hypogonadism-like patients with erectile dysfunction-do not seek medical attention, it is important for clinicians to be acquainted with the signs and symptoms of hypogonadism, and to conduct appropriate laboratory testing and other assessments to determine the causes and inform the treatment of this condition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16094414     DOI: 10.1038/sj.ijir.3901365

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  18 in total

1.  Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: concerns on the detection of doping with testosterone in treated hypogonadal athletes.

Authors:  L Di Luigi; P Sgrò; F Romanelli; M Mazzarino; F Donati; M C Braganò; S Bianchini; V Fierro; M Casasco; F Botrè; A Lenzi
Journal:  J Endocrinol Invest       Date:  2009-03-24       Impact factor: 4.256

2.  Hypogonadism: Easy to define, hard to diagnose, and controversial to treat.

Authors:  Joshua Sterling; Aaron M Bernie; Ranjith Ramasamy
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 3.  Effects of alcohol on the endocrine system.

Authors:  Nadia Rachdaoui; Dipak K Sarkar
Journal:  Endocrinol Metab Clin North Am       Date:  2013-09       Impact factor: 4.741

4.  Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Monika Eichholzer; Aline Barbir; Shehzad Basaria; Adrian S Dobs; Manning Feinleib; Eliseo Guallar; Andy Menke; William G Nelson; Nader Rifai; Elizabeth A Platz; Sabine Rohrmann
Journal:  Aging Male       Date:  2012-07-23       Impact factor: 5.892

5.  Androgens, body fat Distribution and Adipogenesis.

Authors:  Mouna Zerradi; Julie Dereumetz; Marie-Michèle Boulet; André Tchernof
Journal:  Curr Obes Rep       Date:  2014-12

6.  17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate.

Authors:  Joshua F Yarrow; Christine F Conover; Sean C McCoy; Judyta A Lipinska; Cesar A Santillana; John M Hance; Darryl F Cannady; Tisha D VanPelt; Joshua Sanchez; Bryan P Conrad; Jennifer E Pingel; Thomas J Wronski; Stephen E Borst
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-25       Impact factor: 4.310

Review 7.  Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.

Authors:  C Cattabiani; S Basaria; G P Ceda; M Luci; A Vignali; F Lauretani; G Valenti; R Volpi; M Maggio
Journal:  J Endocrinol Invest       Date:  2011-11-08       Impact factor: 4.256

Review 8.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

9.  Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism.

Authors:  Heather L Gelhorn; Margaret K Vernon; Katie D Stewart; Michael G Miller; Meryl Brod; Stanley E Althof; Leonard R DeRogatis; Adrian Dobs; Allen D Seftel; Dennis A Revicki
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.